Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer

Colon Cancer Stage Clinical Trial

Official title:

Evaluation of Anticancer Effect of Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03645187
• Other study ID #: celecoxib
• Status: Recruiting
• Phase: Phase 4
• Start date: August 1, 2018
• Est. completion date: December 2025

Study information

• Verified date: April 2021
• Source: Tanta University
• Contact: Sherief Abd-Elsalam, MD
• Phone: 00201147773440
• Email: sheriefabdelsalam[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aimed at evaluation of anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer

Description:

The primary aim of the study is to evaluate the anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 2025
• Est. primary completion date: August 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• advanced colorectal cancer

Exclusion Criteria:

• cerebral metastases

• other malignancy

• H pylori infection

• thromboembolism

Related Conditions & MeSH terms

• Colon Cancer Stage
• Colorectal Neoplasms

Intervention

Drug:
• FOLFERI
FOLFERI regimen
• Folferi and celecoxib
Folferi regimen and celecoxib

Locations

Country	Name	City	State
Egypt	Amira Roushdy	Tanta	Elgharbia

Sponsors (1)

Lead Sponsor	Collaborator
Sherief Abd-Elsalam

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of patients with improved radiology	number of patients with improved radiology	6 months